Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

BACKGROUND: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients’ mortality. METHODS: 85 cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Capra, Ruggero, De Rossi, Nicola, Mattioli, Flavia, Romanelli, Giuseppe, Scarpazza, Cristina, Sormani, Maria Pia, Cossi, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219361/
https://www.ncbi.nlm.nih.gov/pubmed/32405160
http://dx.doi.org/10.1016/j.ejim.2020.05.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219361/
https://www.ncbi.nlm.nih.gov/pubmed/32405160
http://dx.doi.org/10.1016/j.ejim.2020.05.009

Ejemplares similares